{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T01:23:53Z","timestamp":1773883433289,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ejim.2024.10.019","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T11:17:14Z","timestamp":1730287034000},"page":"47-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Clinically relevant bleeding according to location of metastases in cancer-associated thrombosis"],"prefix":"10.1016","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8359-3531","authenticated-orcid":false,"given":"Victor","family":"Garcia-Garcia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Barca-Hernando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Lopez-Ruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Rosa-Linares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Elias-Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remedios","family":"Otero-Candelera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Andrade-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4125-3376","authenticated-orcid":false,"given":"Luis","family":"Jara-Palomares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2024.10.019_bib0001","doi-asserted-by":"crossref","unstructured":"Timp J.F., Braekkan S.K., Versteeg H.H., Cannegieter S.C. Epidemiology of cancer-associated venous thrombosis 2013. 10.1182\/blood-2013-04.","DOI":"10.1182\/blood-2013-04-460121"},{"key":"10.1016\/j.ejim.2024.10.019_bib0002","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejim.2024.10.019_bib0003","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American society of hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejim.2024.10.019_bib0004","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.10.019_bib0005","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.arbres.2021.01.031","article-title":"Multidisciplinary consensus for the management of pulmonary thromboembolism","volume":"58","author":"Lobo","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.ejim.2024.10.019_bib0006","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO clinical practice guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejim.2024.10.019_bib0007","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2024.10.019_bib0008","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1160\/TH13-02-0132","article-title":"Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism","volume":"110","author":"Lecumberri","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.10.019_bib0009","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1111\/jth.13139","article-title":"Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Chai-Adisaksopha","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.10.019_bib0010","doi-asserted-by":"crossref","first-page":"578","DOI":"10.7326\/0003-4819-152-9-201005040-00008","article-title":"Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism","volume":"152","author":"Carrier","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2024.10.019_bib0011","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1055\/a-2145-7238","article-title":"A novel risk prediction score for clinically significant bleeding in patients anticoagulated for venous thromboembolism with active cancer","volume":"124","author":"Cohen","year":"2024","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.10.019_bib0012","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1055\/s-0041-1735251","article-title":"Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score","volume":"122","author":"De Winter","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.10.019_bib0013","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1538-7836.2010.03852.x","article-title":"Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry","volume":"8","author":"Nieto","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.10.019_bib0014","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.10.019_bib0015","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting Fine-Gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.ejim.2024.10.019_bib0016","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.thromres.2020.12.031","article-title":"Prediction models for recurrence and bleeding in patients with venous thromboembolism: a systematic review and critical appraisal","volume":"199","author":"de Winter","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejim.2024.10.019_bib0017","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.V78.9.2337.2337","article-title":"Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin","volume":"78","author":"Nieuwenhuis","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2024.10.019_bib0018","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1160\/TH08-03-0193","article-title":"Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry","volume":"100","author":"Ru\u00edz-Gim\u00e9nez","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.10.019_bib0019","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.thromres.2013.06.019","article-title":"Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism","volume":"132","author":"Nieto","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejim.2024.10.019_bib0020","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1160\/th15-06-0474","article-title":"Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists","volume":"115","author":"Di Nisio","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.10.019_bib0021","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1183\/13993003.00280-2016","article-title":"Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment","volume":"48","author":"Klok","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejim.2024.10.019_bib0022","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1160\/TH-17-03-0162","article-title":"Derivation and validation of a novel bleeding risk score for elderly patients with venous thromboembolism on extended anticoagulation","volume":"117","author":"Seiler","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.10.019_bib0023","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.chest.2021.06.048","article-title":"An original risk score to predict early major bleeding in acute pulmonary embolism: the syncope, anemia, renal dysfunction (PE-SARD) bleeding score","volume":"160","author":"Chopard","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2024.10.019_bib0024","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/archinte.159.5.457","article-title":"Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism","volume":"159","author":"Kuijer","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejim.2024.10.019_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102194","article-title":"The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis","volume":"64","author":"van Hylckama Vlieg","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ejim.2024.10.019_bib0026","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1055\/a-1647-9896","article-title":"Extended anticoagulant treatment with full- or reduced-dose apixaban in patients with cancer-associated venous thromboembolism: rationale and design of the API-CAT study","volume":"122","author":"Mah\u00e9","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.10.019_bib0027","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/PPO.0000000000000138","article-title":"The contribution of angiogenesis to the process of metastasis","volume":"21","author":"Bielenberg","year":"2015","journal-title":"Cancer J"},{"key":"10.1016\/j.ejim.2024.10.019_bib0028","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1182\/asheducation-2015.1.243","article-title":"Coagulopathy in liver disease: a balancing act","volume":"2015","author":"Kujovich","year":"2015","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ejim.2024.10.019_bib0029","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/bjh.16383","article-title":"Prediction of significant bleeding during vitamin K antagonist treatment for venous thromboembolism in outpatients","volume":"189","author":"Martinez","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2024.10.019_bib0030","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.3324\/haematol.13055","article-title":"Recurrent thromboembolism and major bleeding during oral anticoagulant therapy in patients with solid cancer: findings from the RIETE registry","volume":"93","author":"Prandoni","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.ejim.2024.10.019_bib0031","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1055\/s-0040-1708481","article-title":"A meta-analysis of case fatality rates of recurrent venous thromboembolism and major bleeding in patients with cancer","volume":"120","author":"Abdulla","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.10.019_bib0032","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2023-002273","article-title":"External validation and updating of prediction models of bleeding risk in patients with cancer receiving anticoagulants","volume":"10","author":"Trinks-Roerdink","year":"2023","journal-title":"Open Heart"},{"key":"10.1016\/j.ejim.2024.10.019_bib0033","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14081937","article-title":"In search of the appropriate anticoagulant-associated bleeding risk assessment model for cancer-associated thrombosis patients","volume":"14","author":"Po\u00e9nou","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejim.2024.10.019_bib0034","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","article-title":"Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial","volume":"161","author":"Planquette","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2024.10.019_bib0035","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2024.10.019_bib0036","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.10.019_bib0037","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1111\/jth.15435","article-title":"Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: a systematic review and meta-analysis","volume":"19","author":"Caiano","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.10.019_bib0038","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524004394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524004394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T03:43:29Z","timestamp":1738554209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620524004394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":38,"alternative-id":["S0953620524004394"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2024.10.019","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinically relevant bleeding according to location of metastases in cancer-associated thrombosis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2024.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Federation of Internal Medicine. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}